Zimmer Biomet Set to Release Q3 2025 Earnings on November 5

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is expected to release its financial results for the third quarter of 2025 before markets open on November 5, 2025. Analysts anticipate earnings of $1.87 per share and revenue of approximately $2.0089 billion for the quarter. The company has set its full-year guidance for 2025 at an earnings per share (EPS) range of $8.100 to $8.300.

Investors can access the company’s Q3 2025 earnings overview page for the latest updates. The earnings call is scheduled for 8:30 AM ET on the same day. In the previous quarter, Zimmer Biomet reported an EPS of $2.07, surpassing analysts’ expectations of $1.98 by $0.09. The company achieved revenue of $2.08 billion, exceeding forecasts of $2.06 billion. This reflects a year-over-year revenue increase of 7.0% compared to the same quarter in 2024, where the company earned $2.01 EPS.

Current Stock Performance and Financial Metrics

On November 5, Zimmer Biomet’s stock opened at $101.18. Financial metrics reveal a debt-to-equity ratio of 0.54, a current ratio of 1.87, and a quick ratio of 0.96. The company boasts a market capitalization of $20.04 billion, a price-to-earnings (P/E) ratio of 24.62, and a price-to-earnings growth (P/E/G) ratio of 2.37. Over the past year, the stock has fluctuated between a low of $89.22 and a high of $114.72.

In addition to its financial performance, Zimmer Biomet recently declared a quarterly dividend of $0.24 per share, which will be distributed on October 31, 2025 to shareholders recorded as of September 30, 2025. This dividend represents an annualized yield of 0.9%, with a dividend payout ratio (DPR) currently at 23.36%.

Analyst Ratings and Institutional Involvement

Equities research analysts have varied opinions on Zimmer Biomet’s stock. Evercore ISI recently adjusted its price target from $106.00 to $104.00 while maintaining an “in-line” rating. Roth Capital reaffirmed a “buy” rating on the shares, while Royal Bank of Canada set a target price of $111.00. Meanwhile, UBS Group lowered its target price to $96.00 and assigned a “sell” rating.

Overall, one analyst has rated the stock as a Strong Buy, nine as Buy, eight as Hold, and two as Sell, leading to an average rating of “Hold” with a consensus target price of $111.94 according to MarketBeat.

Recent insider transactions also indicate ongoing interest in the company’s stock. Senior Vice President Lori Winkler sold 1,500 shares at an average price of $104.15, totaling $156,225.00. After this sale, she retains 6,833 shares valued at approximately $711,656.95.

Institutional investors are heavily invested in Zimmer Biomet, owning 88.89% of the company. In recent months, several institutions have either increased or established their stakes in the company. For example, Orion Portfolio Solutions LLC purchased a new position worth approximately $426,000, while Corient Private Wealth LLC boosted its holdings by 78.8% during the second quarter.

Zimmer Biomet Holdings, Inc. continues to operate as a leading medical technology company globally, specializing in orthopedic reconstructive products and various other medical devices. As the company prepares for its upcoming earnings announcement, stakeholders will be closely monitoring its performance and future guidance.